1st Department of Medicine Hematology 1st Faculty of Medicine Charles University and General Hospital Prague Czech Republic

4th Department of Internal Medicine Haematology University Hospital and Faculty of Medicine Hradec Králové Czech Republic

Alfred Hospital and Monash University Melbourne Victoria Australia

Antalya Training and Research Hospital Antalya Turkey

Central European Institute of Technology Masaryk University Brno Czech Republic

Clalit Health Services Jerusalem District Affiliated with the Hebrew University School of Medicine Jerusalem Israel

Clinic for Hematology University Clinical Center of Serbia Belgrade Serbia

Clinical Haematology Belfast City Hospital Belfast UK

Comprehensive Cancer Center Augsburg Faculty of Medicine University of Augsburg Augsburg Germany

Consultative Hematology Department with a Day Hospital for Intensive High Dose Chemotherapy National Medical Research Center for Hematology Moscow Russia

Department and Clinic of Hematology Blood Neoplasms and Bone Marrow Transplantation Wroclaw Medical University Wroclaw Poland

Department of Clinical and Experimental Medicine Section of Hematology University of Pisa Pisa Italy

Department of Haematology Athens Medical Center Psychikon Branch Athens Greece

Department of Haematology Faculty of Medicine School of Health Sciences University of Ioannina Ioannina Greece

Department of Haematology Royal Bournemouth Hospital Bournemouth United Kingdom

Department of Haematology University Hospital of Salamanca Salamanca Spain

Department of Haematology University of Athens Laikon General Hospital Athens Greece

Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic

Department of Hemato Oncology Faculty of Medicine and Dentistry Palacký University and University Hospital Olomouc Olomouc Czech Republic

Department of Hemato Oncology Institut Paoli Calmettes Marseille France

Department of Hematological Malignancies and Stem Cell Transplantation Research Institute of Marques de Valdecilla Santander Spain

Department of Hematology and Bone Marrow transplantation Unit National and Kapodistrian University of Athens Laikon General Hospital Athens Greece

Department of Hematology and Cell Therapy Estaing University Hospital Clermont Ferrand France

Department of Hematology Cancer Center Amsterdam Amsterdam University Medical Centers University of Amsterdam Amsterdam the Netherlands

Department of Hematology Centre Hospitalier Le Mans Le Mans France

Department of Hematology Hospital del Mar Barcelona Spain

Department of Hematology Hospital Universitario de Burgos Burgos Spain

Department of Hematology Oncology and Chemotherapy S P Botkin's City Hospital Moscow Russia

Department of Hematology Shamir Medical Center Zerifin Israel

Department of Hematology Tel Aviv Sourasky Medical Center and Faculty of Medicine Tel Aviv University Tel Aviv Israel

Department of Hematology University Hospital Dubrava Zagreb Croatia

Department of Hematology University Hospital Marqués de Valdecilla Santander Spain

Department of Hematology University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis Greece

Department of Hematology University Hospital Vall d'Hebron Barcelona Spain

Department of Internal Medicine Division of Hematology University Hospital Center Zagreb Zagreb Croatia

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Internal Medicine Postgraduate Institute of Medical Education and Research Chandigarh India

Department of Medical Oncology and Hematology All India Institute of Medical Sciences Rishikesh India

Department of Medicine Faculty of Medicine Kuwait University Kuwait City Kuwait

Department of Medicine Pamela Youde Nethersole Eastern Hospital Chai Wan Hong Kong

Department of Medicine School of Clinical Medicine The University of Hong Kong Hong Kong Hong Kong

Department of Molecular Hematology National Medical Research Center for Hematology Moscow Russia

Department of Pathology Faculty of Medicine University of Augsburg Augsburg Germany

Department of Translational Medicine Division of Hematology University of Eastern Piedmont Novara Italy

Dipartimento di Diagnostica per Immagini Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy

Division of CLL Department of Internal Medicine 3 Ulm University Ulm Germany

Division of Hematology A O U Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences University of Turin Turin Italy

Division of Hematology Dokuz Eylul University Izmir Turkey

Division of Hematology University of Siena Siena Italy

Experimental Hematooncology Department Medical University of Lublin Lublin Poland

Federal State Budgetary Educational Institution of Higher Education Academician 1 P Pavlov 1st St Petersburg State Medical University of the Ministry of Healthcare of Russian Federation St Petersburg Russia

Fujian Provincial Key Laboratory of Hematology Fujian Institute of Hematology Fujian Medical University Union Hospital Fuzhou China

Fundacion Jimenez Diaz University Hospital Health Research Institute IIS FJD Madrid Spain

Gazi University Medical Faculty Ankara Turkey

Haematology Department Hospital Universitario de La Princesa Madrid Spain

Hematology and Oncology Faculty of Medicine University of Augsburg Augsburg Germany

Hematology and Stem Cell Transplantation Unit Ospedale Oncologico A Businco ARNAS G Brotzu Cagliari Italy

Hematology Bnai Zion Medical Center Haifa Israel

Hematology Clinic ASUFC Udine Italy

Hematology Department and HCT Unit G Papanicolaou Hospital Thessaloniki Greece

Hematology Department Colentina Clinical Hospital Bucharest Romania

Hematology Department Hospital Universitario 12 de Octubre Madrid Spain

Hematology Department Infanta Leonor University Hospital Madrid Spain

Hematology Department Ramón y Cajal University Hospital Madrid Spain

Hematology Department St John's Cancer Center Lublin Poland

Hematology Section Department of Medical Oncology National Center for Cancer Care and Research Doha Qatar

Hematology St Anna University Hospital Ferrara Italy

Hematology Unit 1st Dept of Internal Medicine AUTH AHEPA Hospital Thessaloniki Greece

Hematology Unit Department of Medicine University of Padova Padova Italy

Hematology Unit Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan Milan Italy

Hospital de Clinicas Montevideo Uruguay

Hospital Italiano La Plata Buenos Aires Argentina

Hull York Medical School Hull UK

Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece

Institute of Hematology and Center for Hemato Oncology Research University of Perugia and Santa Maria della Misericordia Hospital Perugia Italy

Internal Medicine Department Universidade Federal do Espírito Santo Vila Velha Espírito Santo Brazil

IRCCS Ospedale San Raffaele Milan Italy

Laboratory Medicine and Pathology Hamad Medical Corporation Doha Qatar

Limited Liability Company Multidisciplinary Medical Center for Rehabilitation Treatment ZDOROV'E Gatchina Russia

Molecular Cytogenetics Laboratory Pathology Department Hospital del Mar and Translational Research on Hematological Neoplasms Group Hospital del Mar Research Institute Barcelona Spain

Oncology Center Mansoura University Mansoura Egypt

Peter MacCallum Cancer Centre St Vincent's Hospital University of Melbourne Melbourne Victoria Australia

Royal North Shore Hospital Sydney New South Wales Australia

Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

Service d'Hématologie Oncologie Centre Hospitalier de Versailles Le Chesnay France

Servicio de Hematología Consorcio Hospital General Universitario de Valencia Fundación de Investigación Hospital General Universitario de Valencia Valencia Spain

Sezione di Ematologia Dipartimento di Scienze Radiologiche ed Ematologiche Università Cattolica del Sacro Cuore Rome Italy

Università Vita Salute San Raffaele Milan Italy

University Clinic of Hematology Medical Faculty University Ss Cyril and Methodius Skopje North Macedonia

University of Belgrade Faculty of Medicine Belgrade Serbia

University of Novi Sad Faculty of Medicine Clinical Centre of Vojvodina Novi Sad Serbia

See more in PubMed

Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329:918‐932. PubMed

Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib‐treated patients in the United States: a real‐world analysis. Haematologica. 2018;103:874‐879. PubMed PMC

Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353‐1363. PubMed PMC

Ghia P, Pluta A, Wach M, et al. Ascend: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849‐2861. PubMed

Mattsson A, Sylvan SE, Axelsson P, et al. Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: a Swedish nation‐wide real‐world report on consecutively identified patients. Eur J Haematol. 2023;111:715‐721. PubMed

Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open‐label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37:1391‐1402. PubMed PMC

Eyre TA, Roeker LE, Fox CP, et al. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. Br J Haematol. 2020;188:918‐923. PubMed PMC

Fischer K, Al‐Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225‐2236. PubMed

Mato AR, Thompson M, Allan JN, et al. Real‐world outcomes and management strategies for venetoclax‐treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103:1511‐1517. PubMed PMC

Roeker LE, Fox CP, Eyre TA, et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax‐treated CLL patients in routine clinical practice. Clin Cancer Res. 2019;25:4264‐4270. PubMed PMC

Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax‐rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107‐1120. PubMed

Scarfo LAE, Quaglia FM, Marasca R, Sanna A, Murru R, Laurenti L. An observational study on patients with relapsed/refractory chronic lymphocytic leukemia treated with venetoclax‐based regimens outside clinical trials in Italy (GIMEMA CLL1920). Blood. 2021;138(Supplement 1):3746.

Stilgenbauer S, Tausch E, Roberts AW, et al. Six‐year follow‐up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood Adv. 2024;8(8):1992‐2004. PubMed PMC

Lew TE, Lin VS, Cliff ER, et al. Outcomes of patients with cll sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5:4054‐4058. PubMed PMC

Mato AR, Hess LM, Chen Y, et al. Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: a real‐world database study. Clin Lymphoma Myeloma Leuk. 2023;23:57‐67. PubMed